tbuckley/cabot-search huggingface dataset:
A Randomized Trial of the Safety and Benefit of Transfusion Vs. Standard Care In the Prevention of Sickle Cell-Related Complications In Adults: a Preliminary Report From the Phase II NHLBI Comprehensive Sickle Cell Centers (CSCC) Study of Neuropsychological Dysfunction and Neuroimaging Abnormalities In Neurologically Intact Adult Patients with Sickle Cell Disease
Authors: Elliott Vichinsky, Lynne Neumayr, Jeffrey I Gold, Michael W Weiner, Jeffrey Kasten, Diana Truran, Cathie Snyder, Karen Kesler, Atif Mahmoud Hussein, Thomas J. Harrington, Lillian McMahon, Victor R. Gordeuk, Abdullah Kutlar, Eugene P. Orringer, Laura M. De Castro, Joshua Field, Paul S. Swerdlow, Joel David Bessman, Richard Snyder, John J. Strouse, F. Daniel Armstrong
Journal: Blood (2010)
CD19 Targeted Allogeneic EBV-Specific T Cells for the Treatment of Relapsed ALL in Pediatric Patients Post HSCT
Authors: Kevin J. Curran, Nancy A. Kernan, Xiuyan Wang, Clare Taylor, Ekaterina Doubrovina, Shirley Bartido, Michel Sadelain, Richard J. O'Reilly, Renier J Brentjens, Isabelle Rivière
Journal: Blood (2012)
Does Lack of “Genetic-Relative Family Health History” Represent a Potentially Avoidable Health Disparity for Adoptees?
Authors: Thomas May, Kimberly A. Strong, Kaija L. Zusevics, Jessica Jeruzal, Michael H. Farrell, Alison LaPean Kirschner, Arthur R. Derse, James P. Evans, Harold D. Grotevant
Journal: The American Journal of Bioethics (2016)

Many adoptees face a number of challenges relating to separation from biological parents during the adoption process, including issues concerning identity, intimacy, attachment, and trust, as well as (for older adopted children) language and other cultural challenges. One common health challenge faced by adoptees involves lack of access to genetic-relative family health history (GRFHx). Lack of GRFHx represents a disadvantage due to a reduced capacity to identify diseases and recommend appropriate screening for conditions for which the adopted person may be at increased risk. In this article, we draw out common features of traditionally understood "health disparities" in order to identify analogous features in the context of adoptees' lack of GRFHx.
Positive Direct Antiglobulin Test (DAT) in Chronic Lymphocytic Leukemia (CLL) Patients: Correlation with Prognostic Factors.
Authors: Francesca Ricci, Alessandra Tedeschi, Eleonora Vismara, Antonino Greco, Chiara Colombo, Anna Colosimo, Michele Nichelatti, Roberto Cairoli, Enrica Morra, Marco Montillo
Journal: Blood (2009)
Results of an Exploratory Study of Oral (po) and Intravenous (iv) Clofarabine in Patients with Myelodysplastic Syndrome.
Authors: Stefan Faderl, Guillermo Garcia-Manero, Varsha Gandhi, Farhad Ravandi, Gautam Borthakur, Deborah A. Thomas, Alessandra Ferrajoli, Zeev Estrov, William Plunkett, Anna Byrd, Monica Kwari, Hagop M. Kantarjian
Journal: Blood (2007)
Daratumumab, a Novel Human CD38 Monoclonal Antibody for Treatment of Multiple Myeloma, Prevents Intra-Medullary Spreading of Patient Derived Multiple Myeloma Cells Growing in a Humanized Mouse Model
Authors: Willy A Noort, Richard W.J. Groen, Reinier Raymakers, Linda Aalders, Joost de Bruijn, Huipin Yuan, Jeroen Lammerts van Bueren, Paul W.H.I. Parren, Henk Lokhorst, Tuna Mutis, Anton C.M. Martens
Journal: Blood (2012)
Feasibility and Outcomes of Haploidentical Transplantation for Elderly Patients with Advanced Hematological Malignancies: The MD Anderson Cancer Center Experience
Authors: Sameh Gaballa, Piyanuch Kongtim, Gabriela Rondon, Julianne Chen, Uday Popat, Sairah Ahmed, Chitra M Hosing, Betul Oran, Partow Kebriaei, Simrit Parmar, Nina Shah, Issa F. Khouri, Richard E. Champlin, Stefan O. Ciurea
Journal: Blood (2014)
Targeting Hsp70 in Multiple Myeloma Induces Synergistic Cytotoxicity with Inhibitors of the Proteasome and of Hsp90
Authors: Marc J Braunstein, Craig M Scott, Shannon Behrman, Peter Walter, Peter Wipf, Eric LP Smith, Sadeaqua S Scott, H. Uwe Klueppelberg, Jeffrey L Brodsky, Olcay Batuman
Journal: Blood (2008)
Enhanced Respiratory Chain Supercomplex Formation in Response to Exercise in Human Skeletal Muscle
Authors: Chiara Greggio, Pooja Jha, Sameer S. Kulkarni, Sylviane Lagarrigue, Nicholas T. Broskey, Marie Boutant, Xu Wang, Sonia Conde Alonso, Emmanuel Ofori, Johan Auwerx, Carles Cantó, Francesca Amati
Journal: Cell Metabolism (2016)
THREE-DIMENSIONAL ECHOCARDIOGRAPHIC ASSESSMENT OF THE LONGITUDINAL TRICUSPID VALVE CHANGES ASSOCIATED WITH TRICUSPID REGURGITATION IN HYPOPLASTIC LEFT HEART SYNDROME
Authors: Timothy Colen, Shelby Kutty, Richard Thompson, Chodchanok Vijarnsorn, Jeffrey F. Smallhorn, Nee S. Khoo
Journal: Journal of the American College of Cardiology (2013)
Hepatic Encephalopathy Is Associated With Mortality in Patients With Cirrhosis Independent of Other Extrahepatic Organ Failures
Authors: Jasmohan S. Bajaj, Jacqueline G. O’Leary, Puneeta Tandon, Florence Wong, Guadalupe Garcia-Tsao, Patrick S. Kamath, Benedict Maliakkal, Scott W. Biggins, Paul J. Thuluvath, Michael B. Fallon, Ram M. Subramanian, Hugo E. Vargas, Jennifer Lai, Leroy R. Thacker, K. Rajender Reddy
Journal: Clinical Gastroenterology and Hepatology (2016)
Correction of Immunodeficiency Associated with NEMO Mutation by Umbilical Cord Stem Cell Transplantation Using a Reduced-Intensity Conditioning Regimen.
Authors: Chikako Tono, Yoshihiro Takahashi, Kiminori Terui, Shinya Sasaki, Takuya Kamio, Satoru Tandai, Tomohiko Sato, Ko Kudo, Tsutomu Toki, Naoki Tachibana, Takakazu Yoshioka, Tatsutoshi Nakahata, Tomohiro Morio, Ryuta Nishikomori, Etsuro Ito
Journal: Blood (2006)
Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial
Authors: Eirik Søfteland, Juris J. Meier, Bente Vangen, Robert Toorawa, Mario Maldonado-Lutomirsky, Uli C. Broedl
Journal: Diabetes Care (2016)

OBJECTIVE To evaluate the efficacy and safety of empagliflozin versus placebo as add-on therapy in patients with type 2 diabetes and inadequate glycemic control with linagliptin and metformin. RESEARCH DESIGN AND METHODS Patients with HbA1c ≥8.0% and ≤10.5% (≥64 and ≤91 mmol/mol) while receiving stable-dose metformin received open-label linagliptin 5 mg (n = 606) for 16 weeks. Subsequently, those with HbA1c ≥7.0 and ≤10.5% (≥53 and ≤91 mmol/mol) were randomized to receive double-blind, double-dummy treatment with empagliflozin 10 mg (n = 112), empagliflozin 25 mg (n = 111), or placebo (n = 110) for 24 weeks; all patients continued treatment with metformin and linagliptin 5 mg. The primary end point was the change from baseline in HbA1c after 24 weeks of double-blind treatment. RESULTS At week 24, empagliflozin significantly reduced HbA1c (mean baseline 7.96–7.97% [63–64 mmol/mol]) versus placebo; the adjusted mean differences in the change from baseline with empagliflozin 10 and 25 mg versus placebo were −0.79% (95% CI ‒1.02, ‒0.55) (−8.63 mmol/mol [‒11.20, ‒6.07 mmol/mol]) and −0.70% (95% CI ‒0.93, ‒0.46) (−7.61 mmol/mol [‒10.18, ‒5.05 mmol/mol]), respectively (both P &amp;lt; 0.001). Fasting plasma glucose and weight were significantly reduced in both empagliflozin groups versus placebo (P &amp;lt; 0.001 for all comparisons). More patients receiving placebo than empagliflozin 10 and 25 mg reported adverse events during double-blind treatment (68.2%, 55.4%, and 51.8%, respectively). CONCLUSIONS Empagliflozin treatment for 24 weeks improved glycemic control and weight versus placebo as an add-on to linagliptin 5 mg and metformin and was well tolerated.
Dexamethasone and Cyclophosphamide: More Convenient and as Effective as VAD before High-Dose Melphalan and Autologous Transplantation in Newly Diagnosed Multiple Myeloma. Results of a Randomized NMSG Trial.
Authors: Ulf-Henrik Mellqvist, Stig Lenhoff, Martin Hjorth, Erik Holmberg, Gunnar Juliusson, Jon Magnus Tangen, Jan Westin, Hans Johnsen
Journal: Blood (2006)
Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor Rocilinostat (ACY-1215) and Bortezomib, Demonstrates Synergistic Antitumor Activity in Preclinical Models of Lymphoma
Authors: Jennifer E Amengual, Paul M Johannet, Simon S Jones, Owen A. O'Connor
Journal: Blood (2012)
Unique Pattern of Raf-1 Kinase Inhibitory Protein (RKIP) Expression in Multiple Myeloma (MM) Compared to Other Tumor Types: Overexpression of RKIP and a Phosphorylated RKIP Is Common in MM Tumor Cells.
Authors: Stavroula Baritaki, Sara Huerta-Yepez, Kam Yeung, Manuel Penichet, Haiming Chen, Dror Shalitin, James Berenson, Benjamin Bonavida
Journal: Blood (2007)
The Complete Mutatome and Clonal Architecture of Del(5q)
Authors: Vera Ademà, Laura Palomo, Przychodzen P Bartlomiej, Diez-campelo Maria, Naoko Hosono, Mar Mallo, Blanca Xicoy, Elisa Luño, Bhumika J. Patel, Cassandra M Hirsch, Lurdes Zamora, Thomas LaFramboise, Leonor Arenillas, Albert Perez-Ladaga, Carme Pedro, Michael J. Clemente, Joan Bargay, Julia Montoro, Juan Carlos Caballero, Brayan Merchan, Victor Noriega, Victor Marcos-Betes, Consuelo Del Cañizo, Rosario Lopez, José María Raya, Joaquin Sanchez-Garcia, Eduardo Rios, Montserrat Arnan, Lourdes Florensa, Raquel de Paz, Angelina Lemes, Paula Gomez-Marzo, Nuri Haro, Francisco Fuster-Tormo, Monica Bayes, Ivo Gut, Rafael Bejar, Mikkael A. Sekeres, Jaroslaw P. Maciejewski, Francesc Sole
Journal: Blood (2015)
Thymic Stromal Lymphopoeitin Signaling Contributes To Increased Risk Of Relapse Of Pediatric Acute Lympoblastic Leukemia Through Enhanced Survival Of Leukemic Cells That Overexpress Thymic Stromal Lymphopoeitin Receptor
Authors: Christopher D Chien, Matthew Kreitman, Haiying Qin, Terry J Fry
Journal: Blood (2013)
Targeting the mTOR Pathway Suppresses the Growth of Acute Myeloid Leukemia (AML) Progenitors and Enhances Arsenic Trioxide Induced Antileukemic Responses.
Authors: Jessica K. Altman, Antonella Sassano, Patrick J. Yoon, Amanda J. Redig, Efstratios Katsoulidis, Martin S. Tallman, Leonidas C. Platanias
Journal: Blood (2006)
Differential Gene Expression Patterns and Interaction Networks in BCR/ABL Positive and Negative Adult Acute Lymphoblastic Leukemias.
Authors: Dejan Juric, Norman J. Lacayo, Meghan C. Ramsey, Janis Racevskis, Peter H. Wiernik, Jacob M. Rowe, Anthony H. Goldstone, Peter J. O’Dwyer, Elisabeth Paietta, Branimir I. Sikic
Journal: Blood (2006)
Long-Term Follow-Up of Patients with T-Large Granular Lymphocyte Leukemia (T-LGL); Experience in a Single Institution.
Authors: Ahmed Aribi, Michael Keating, Susan O’Brien, Alessandra Ferrajoli, Stefan Faderl, Susan Lerner, Charles Koller, William Wierda, Jorge Cortes, Hagop Kantarjian, Farhad Ravandi-Kashani
Journal: Blood (2005)
Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies
Authors: Martín F. Ortiz-Genga, Sofía Cuenca, Matteo Dal Ferro, Esther Zorio, Ricardo Salgado-Aranda, Vicente Climent, Laura Padrón-Barthe, Iria Duro-Aguado, Juan Jiménez-Jáimez, Víctor M. Hidalgo-Olivares, Enrique García-Campo, Chiara Lanzillo, M. Paz Suárez-Mier, Hagith Yonath, Sonia Marcos-Alonso, Juan P. Ochoa, José L. Santomé, Diego García-Giustiniani, Jorge L. Rodríguez-Garrido, Fernando Domínguez, Marco Merlo, Julián Palomino, María L. Peña, Juan P. Trujillo, Alicia Martín-Vila, Davide Stolfo, Pilar Molina, Enrique Lara-Pezzi, Francisco E. Calvo-Iglesias, Eyal Nof, Leonardo Calò, Roberto Barriales-Villa, Juan R. Gimeno-Blanes, Michael Arad, Pablo García-Pavía, Lorenzo Monserrat
Journal: Journal of the American College of Cardiology (2016)
CBIO-15NON-METABOLIC FUNCTION OF PHOSPHOFRUCTOKINASE-1 IN GLIOBLASTOMA MAINTENANCE
Authors: Kamilla E. Jensen, Elisabeth A. A. Obara, Madhavsai K. Gajjar, Rikke D. Rasmussen, Jiri Bartek, Jane Skjøth-Rasmussen, Jannick Brennum, Jeremy N. Rich, Petra Hamerlik
Journal: Neuro-Oncology (2015)

BACKGROUND: Glioblastoma multiforme (GBM) remains one of the most lethal tumors and is associated with a median survival of only approximately 15 months, despite aggressive combination radio-chemo-therapy. Regardless of recent advances in our understanding of this deadly disease, the molecular mechanisms/genes that cause high recurrence rates and treatment resistance in GBM are poorly understood. It is commonly known that cancer cells including GBM utilize glucose as their main energy source, a phenomenon known as the Warburg effect. Phosphofructosekinase-1 (PFK-1) is one of two rate-limiting enzymes in glycolysis and presents a potential critical control point for these glucose ‘addictive’ cells. In this study we investigated the role of PFK-1 and its effect on cell proliferation and maintenance of GBM. METHODS: To elucidate the role of PFK-1 in GBM, we abrogated its function using shRNA-mediated knockdown or chemical inhibition. Next, we evaluated the cellular responses utilizing a broad range of in vitro assays (cell viability, apoptosis, cell cycle, DNA damage checkpoint activation) under unperturbed and/or genotoxic stress conditions. RESULTS: Inhibition of PFK-1 led to decreased viability, cell cycle de-regulation and increased rates of apoptosis. Furthermore, impaired function of PFK-1 affected cytoskeleton assembly and IR-induced checkpoint activation. CONCLUSION: The novel role of PFK-1 identified in our studies, together with successful therapeutic targeting in vitro and in vivo, furthers our understanding of the role that glycolysis plays in GBM maintenance and therapeutic resistance.
Good Efficacy of Single Dose PEG-Filgrastim in Enhancing the Mobilization of CD34+ Peripheral Blood Stem Cells (PBSC) in Aggressive Lymphoma Patients Treated with Cisplatin-Containing Regimens.
Authors: Annamaria Nosari, Claudia Baraté, Liliana Intropido, Denis Ciapanna, Roberto Cairoli, Livio Gargantini, Laura Pezzetti, Valentina Mancini, Erica Ravelli, Francesca Ricci, Roberto Ripamonti, Enrica Morra
Journal: Blood (2005)
Atomic Level Description of the Immune Complex That Causes Heparin-Induced Thrombocytopenia (HIT)
Authors: Zheng Cai, Serge V. Yarovoi, Zhiquiang Zhu, Lubica Rauova, Tatiana Lebedeva, Mortimer Poncz, Gowthami M Arepally, Douglas B. Cines, Mark I. Greene
Journal: Blood (2014)
Preclinical Efficacy and Toxicology Studies of APR-246, a Novel Anticancer Compound Currently In Clinical Trials for Refractory Hematological Malignancies and Prostate Cancer
Authors: Nina Mohell, Charlotta Liljebris, Jessica Alfredsson, Ylva Lindman, Maria Uustalu, Thomas Uhlin, Mats R.H. Linderholm, Klas G. Wiman
Journal: Blood (2010)
Addition of Purine Analogues to Induction/Consolidation Regimen Does Not Impair Peripheral Blood Stem Cell Mobilization and Bone Marrow Harvest for Autotransplantation in Acute Myeloid Leukemia.
Authors: Jerzy Holowiecki, Sebastian Grosicki, Andrzej Hellmann, Aleksander Skotnicki, Wieslaw W. Jedrzejczak, Anna Dmoszynska, Bozena Marianska, Tadeusz Robak, Sebastian Giebel, Jerzy Wojnar, Malgorzata Krawczyk-Kulis, Maria Wojciechowska
Journal: Blood (2004)
Heatshock Protein (HSP) Family Expression Is Dichotomous and Prognostic in Acute Myelogenous Leukemia (AML)
Authors: Steven M. Kornblau, Chenyue W Hu, Yihua Qiu, Suk Young Yoo, Trang T Nguyen, Tapan Kadia, Gautam Borthakur, Kevin Coombes, Amina A Qutub
Journal: Blood (2014)
Gene Expression Profiling of Myeloma Cells To Predict Response to Primary Therapy with Thalidomide-Dexamethasone for Newly Diagnosed Multilple Myeloma.
Authors: Abderrahman Abdelkefi, John de Vos, Said Assou, Tarek Ben Othman, Jean-Francois Rossi, Saloua Ladeb, Ines Safra, Yosr Galai, Malika Ben Ahmed, Alia Benkahla, Faouzi Jenhani, Moufida Ben Nasr, Lamia Torjman, Amel Lakhal, Hechmi Louzir, Abdeladhim Ben Abdeladhim
Journal: Blood (2007)
Synergistic Reactivation Of Cancer/Testis Antigens By Combination Treatment With Decitabine and Histone Deacetylase Inhibitors (Valproate, Panobinostat) In Myeloid Leukemia Cells
Authors: Nadja Blagitko-Dorfs, Tobias Bauer, Maren Prinz, Wolfram Brugger, Gesine Bug, Katharina Goetze, Michael Heuser, Sabine Kayser, Hans Walter Lindemann, Helmut R. Salih, Björn W. Hackanson, Michael Lübbert
Journal: Blood (2013)
Four Cases of Donor Cell-Derived Acute Myeloid Leukemia Following Unrelated Cord Blood Transplantation for Adult Patients; Tokyo Cord Blood Bank Experiences.
Authors: Tokiko Nagamura-Inoue, Hideki Kodo, Tsuneo A. Takahashi, Hideo Mugishima, Arinobu Tojo, Shigetaka Asano
Journal: Blood (2006)
Inducible MyD88/CD40 Allows Rimiducid-Dependent Activation to Control Proliferation and Survival of Chimeric Antigen Receptor-Modified T Cells
Authors: Aaron Foster, Aruna Mahendravada, Nicholas P Shinners, Peter Chang, An Lu, Eva Morschl, Joanne Shaw, Sunandan Saha, Kevin M Slawin, David M Spencer
Journal: Blood (2015)
Characterization of the Pharmacokinetics of rFVIII in Young Pre-School Children with Hemophilia, Including an Analysis of the Influence of Age and Body Weight.
Authors: Victor Blanchette, Amy D. Shapiro, Raina Liesner, Fernando Hernandez, Anastassios D. Retzios, Phillip Schroth, Sandor Fritsch, Gerald Spotts, Bruce M. Ewenstein
Journal: Blood (2004)
Development of a Bruton's Tyrosine Kinase (Btk) Inhibitor, ONO-WG-307: Efficacy in ABC-DLBCL Xenograft Model – Potential Treatment for B-Cell Malignancies,
Authors: Ryohei Kozaki, Toshio Yoshizawa, Shuji Tohda, Tomoko Yasuhiro, Shingo Hotta, Yuko Ariza, Yoshiko Ueda, Masami Narita, Kazuhito Kawabata
Journal: Blood (2011)
Induction of Potent Anti-Tumor Effects by Original and TCR-Redirected CD4 + Cytotoxic T Cells.
Authors: Robbert M Spaapen, Kelly van den Oudenalder, Maureen van Elk, Tineke Aarts, Teun Guichelaar, Richard WJ Groen, Andries C Bloem, Gert Storm, Anton C Martens, Henk M Lokhorst, Tuna Mutis
Journal: Blood (2009)
Pre-Transplant Beta2-Microglobulin Is an Independent Biomarker of Acute Graft-Versus-Host-Disease after Allogeneic Hematopoietic Cell Transplant in a Single Institutional Study
Authors: Carolina Costa-Lima, Eliana Cristina Martins Miranda, Marcos Paulo Colella, Francisco José Penteado Aranha, Carmino Antônio De Souza, Afonso Celso Vigorito, Erich Vinicius De Paula
Journal: Blood (2015)
Doxil, Vincritine, Reduced Frequency Dexamethasone in Combination with Thalidomide (DVd-T) Is Associated with Higher Overall and Progression Free Survival as Compared to DVd in Patients with Multiple Myeloma (MM).
Authors: Khaldoun Almhanna, Revathi Suppiah, Rachid Baz, Mary Ann Karam, Beth Faiman, Janice Reed, Mohamad Hussein
Journal: Blood (2005)
Oncological and Hematological Neoplasms: Concomitant Oral Anticoagulation Therapy
Authors: Serena Rupoli, Lidia Da Lio, Anna Rita Scortechini, Francesca Ravaglia, Stefano Pulini, Simonetta Mulattieri, Paola Picardi, Lucia Canafoglia, Andrea Stronati, Simona Tomassetti, Massimo Tocchini, Pietro Leoni
Journal: Blood (2008)
No More Militaristic and Violent Language in Medicine: Response to Open Peer Commentaries on “Healing Without Waging War: Beyond Military Metaphors in Medicine and HIV Cure Research”
Authors: Jing-Bao Nie, Stuart Rennie, Adam Gilbertson, Joseph D. Tucker
Journal: The American Journal of Bioethics (2016)

Cell Wars" which explores innovative immunotherapy to "combat" cancer.The new article entitled "Setting the Body's 'Serial Killer's Loose on Cancer" reports a "daring" new treatment "after a long, intense pursuit" (Pollack 2016).For the pioneering researchers and the reporting journalist, the patient's T-cells are considered the "soldiers" of the immune system.Genetically engineered, multiplied in the laboratory, and injected back into the patient's blood in millions or billions, the cells are charged like "a vast army of tumor assassins" to "destroy" cancer cells.In the spirit of heroic warriors, one researcher expressed wishes to "conquer" cancer before his death to "end this Holocaust".Throughout the article (around 5,000 words in length), "kill" or "killer" is used 16 times, "destroy" seven times, and "fight" seven times (one of researchers' fights was not with cancer but over credit).Words such as "healing" or "care" do not appear at all.Why has the language of medicine-the art and science of healing-become so violent?Are militaristic metaphors really necessary and ethically justifiable?In our original article, we utilized an interdisciplinary literature review, transcultural dialogue, and philosophical analysis to examine the historical-cultural roots of ubiquitous military metaphors in medicine (and particularly HIV cure research).We identified a series of perils involved, and proposed a more peaceful one-the journey metaphor-as an alternative.We concluded that, ethically speaking, the violent metaphors in medicine are "ironic, unfortunate, and unnecessary".
O083 : Absence of BSEP/ABCB11 protects from cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis
Authors: C.D. Fuchs, G. Paumgartner, A. Wahlström, P. Chiba, T. Stojakovic, T. Claudel, H.-U. Marschall, M. Trauner
Journal: Journal of Hepatology (2015)
Molecular Genetics of Endometrial Carcinoma
Authors: Daphne W. Bell, Lora Hedrick Ellenson
Journal: Annual Review of Pathology Mechanisms of Disease (2018)

Endometrial cancer is the most commonly diagnosed gynecologic malignancy in the United States. Endometrioid endometrial carcinomas constitute approximately 85% of newly diagnosed cases; serous carcinomas represent approximately 3-10% of diagnoses; clear cell carcinoma accounts for <5% of diagnoses; and uterine carcinosarcomas are rare, biphasic tumors. Longstanding molecular observations implicate PTEN inactivation as a major driver of endometrioid carcinomas; TP53 inactivation as a major driver of most serous carcinomas, some high-grade endometrioid carcinomas, and many uterine carcinosarcomas; and inactivation of either gene as drivers of some clear cell carcinomas. In the past decade, targeted gene and exome sequencing have uncovered additional pathogenic aberrations in each histotype. Moreover, an integrated genomic analysis by The Cancer Genome Atlas (TCGA) resulted in the molecular classification of endometrioid and serous carcinomas into four distinct subgroups, POLE (ultramutated), microsatellite instability (hypermutated), copy number low (endometrioid), and copy number high (serous-like). In this review, we provide an overview of the major molecular features of the aforementioned histopathological subtypes and TCGA subgroups and discuss potential prognostic and therapeutic implications for endometrial carcinoma.
Safety and Early Efficacy Analysis of a Novel Combination of the PARP Inhibitor Veliparib (ABT-888) Plus Bendamustine and Rituximab in Patients with Lymphoma
Authors: John F. Gerecitano, Paul Hamlin, Steven M. Horwitz, Matthew J Matasar, Alison J. Moskowitz, Craig H. Moskowitz, Ariela Noy, Carol S Portlock, Maria Lia Palomba, David J. Straus, Anas Younes, Andrew D. Zelenetz, Alice Chen, Richard F Little, France Fallon, Juho Whang
Journal: Blood (2014)
Authors' response to a reply to ‘A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients’
Authors: D.L. Damian, A.J. Martin, R.A. Scolyer, A.C. Chen, G.M. Halliday
Journal: British Journal of Dermatology (2016)

We thank Yelamos et al. for their interest in our nicotinamide chemoprevention studies.1 Some of their comments are pertinent, while others are based on a flawed interpretation of our data.

Zhao2 previously commented on (nonsignificant) numerical differences in the frequency of adverse-event term groupings (mucocutaneous infections) between the placebo and nicotinamide groups in our ONTRAC chemoprevention study (Oral Nicotinamide To Reduce Actinic Cancer).3 As stated previously, chance remains a highly plausible explanation for the numerically higher mucocutaneous infections in the nicotinamide arm and also, for example, for the numerically lower respiratory infections observed in the nicotinamide arm.4

This article is protected by copyright. All rights reserved.
A Novel Prognostic Model in Heavily Treated Patients with Myelodysplastic Syndromes (MDS)
Authors: Aziz Nazha, David J. Seastone, Tomas Radivoyevitch, Aaron T. Gerds, Sudipto Mukherjee, Hetty E. Carraway, Anjali S. Advani, Matt E. Kalaycio, Gina Rupp, Kristin Colaluka, Sean Hobson, Jaroslaw P. Maciejewski, Mikkael A. Sekeres
Journal: Blood (2014)